

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 37109/11/2000
U.S. APPLICATION NO. (IF KNOWN SEE) 71CFR 151
&@ 525 Rec'd PCT/PTO 01 DEC 2000INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE
PCT/AU99/00424 2 JUNE 1999PRIORITY DATE CLAIMED
2 JUNE 1998

TITLE OF INVENTION: PURIFICATION OF ANTIBODIES

APPLICANT(S) FOR DO/EO/US: DENNIS BRIAN RYLATT of 10 Stuart Street, Ryde, New South Wales, 2112, Australia
SHARON LIM of 28/61-89 Buckingham Street, Surrey Hills, New South Wales, 2010, Australia

APPLICANT HEREWITH SUBMITS TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) THE FOLLOWING ITEMS AND OTHER INFORMATION

1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
 2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
 3. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
 4. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.

5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 a. is transmitted herewith (required only if not transmitted by the International Bureau).
 b. has been transmitted by the International Bureau.
 c. is not required, as the application was filed in the United States Receiving Office (RO/US).
 6. A translation of the International Application into English (35 U.S.C. 371(c)(2)).

7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 a. are transmitted herewith (required only if not transmitted by the International Bureau).
 b. have been transmitted by the International Bureau.
 c. have not been made; however, the time limit for making such amendments has NOT expired.
 d. have not been made and will not be made.

8. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).

9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).

10. A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). It is requested the examination be based on:
 a. the claims as originally filed.
 b. the claims as amended under PCT Article 19.
 c. the claims as annexed to the International Preliminary Examination Report.
 d. the claims as amended by the enclosed Preliminary Amendment.

11. Applicant(s), by its/their undersigned attorney, claims Small Entity Status under 37 C.F.R. §1.27 as an Independent Inventor, or a Small Business Concern, or a Non-Profit Organization.

ITEMS 12. TO 21. BELOW CONCERN DOCUMENT(S) OR INFORMATION INCLUDED:

12. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.

13. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.

14. A **FIRST** preliminary amendment.
 A **SECOND** or **SUBSEQUENT** preliminary amendment.

15. A substitute specification.

16. A change of power of attorney and/or address letter.

17. A copy of the cover sheet of the PCT publication of the application (WO 99/62937).

18. A copy of the International Preliminary Examination Report.

19. An English translation of the International Preliminary Examination Report.

20. Formal drawings (3 sheet).

21. Other items or information: PCT Notification of the Recording of a Change dated April 4, 2000;
 Corrected International Preliminary Examination Report with amended pages submitted under Article 34 (pp 1-4, 12 and 14 - 16) and
 A pre-paid postage return postcard – please stamp and return.

COPY

22. [x] The following fees are submitted (enter lowest fee applicable).

BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):

Search Report has been prepared by the EPO or JPO \$860.00

International preliminary examination fee paid to USPTO (37 CFR 1.482)
..... \$670.00No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search
fee paid to USPTO (37 CFR 1.445(a)(2)) \$710.00Neither international preliminary examination fee (37 CFR 1.482) nor international search fee
(37 CFR 1.445(a)(2)) paid to USPTO \$1,000.00International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied
provisions of PCT Article 33(2)(4) \$1,000.00**ENTER APPROPRIATE BASIC FEE AMOUNT = \$1,000.00**Surcharge of \$130.00 for furnishing the oath or declaration later than [&@] 20 or [&@] 30 months from the earliest claimed
priority date (37 CFR 1.492(e)). \$ 0.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	21 - 20 =	1	x \$ 18.00 =
Independent claims	2 - 3 =	0	x \$ 80.00 =
MULTIPLE DEPENDENT CLAIM(S) (if applicable)	=	10	+ \$270.00 =
TOTAL OF ABOVE CALCULATIONS =			\$1,288.00

Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement indicated below as a result of 9/00
Rule Change (Note 37 CFR 1.9, 1.27, 1.28).

[x] Applicant(s), by its/their undersigned attorney, claim(s) Small Entity Status under 37 C.F.R. §1.27 as []
 [] an Independent Inventor, or [x] a Small Business Concern, or [] a Non-Profit Organization.

SUBTOTAL = \$ 644.00

Processing fee of \$130.00 for furnishing the English translation later than [&@] 20 or [&@] 30 months from the earliest
claimed priority date (37 CFR 1.492(f)). + \$ 0**TOTAL NATIONAL FEE = \$ 644.00****TOTAL FEES ENCLOSED = \$ 644.00**

Amount to be:	
Refunded	\$
Charged	\$

- a. [x] A check in the amount of **\$ 644.00** to cover the above fees is enclosed.
- b. [] Please charge my Deposit Account No. 50-1017 in the amount of **\$ 644.00** to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. [x] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-1017. A duplicate copy of this sheet is enclosed.

NOTE: WHERE AN APPROPRIATE TIME LIMIT UNDER 37 CFR 1.494 OR 1.495 HAS NOT BEEN MET, A PETITION TO REVIVE (37 CFR 1.137(a) OR (b)) MUST BE FILED AND GRANTED TO RESTORE THE APPLICATION TO PENDING STATUS.

SEND ALL CORRESPONDENCE TO.

Customer No. 000027000

AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.
1333 New Hampshire Avenue, N.W.
Washington, D.C. 20036
Telephone: (202) 887-4000 - Direct Dial: (202) 887-4149
Facsimile: (202) 955-7613

Alex Charbove
ALEX CHARBOVE

31,942
REGISTRATION NUMBER

09 / 701818

1

PTO/USPTO Rec'd 11 DEC 2000

Purification of Antibodies

Technical Field

The present invention relates to methods suitable for purification of antibodies, particularly monoclonal antibodies from ascites fluid.

5 Background Art

The processing of complex biological solutions is a major bottleneck in the biotechnology industry and there is a strong demand for cost effective technologies for the purification of naturally occurring and recombinant proteins. This is particularly true for antibodies including monoclonal 10 antibodies, where there has been an on-going search for simple generic methods of purification. In particular, monoclonal antibodies have had an increasing number of research, therapeutic and diagnostic applications since their initial production in 1975. The difficulties in bioprocessing have meant that recoveries of monoclonal antibodies in existing purification schemes are rarely reported but are often in the range of 10 to 70%. Although new 15 processes have become increasingly effective in terms of yield and recovery, commonly used processes often utilise harsh pH or ionic strength conditions for elution which may not always be compatible with maintaining maximal biological activity of antibodies.

20 The present inventor has found that preparative electrophoresis using Gradiflow technology (AU 601040) is particularly suitable for the purification of antibodies. In contrast to conventional methods, Gradiflow uses mild, non-denaturing buffers and conditions which may be utilised to produce more active antibody preparations.

25 Disclosure of Invention

In a first aspect, the present invention consists in a method of separation of an antibody from a mixture of the antibody and at least one contaminant, the method comprising:

30 (a) placing the antibody and contaminant mixture in a first solvent stream, the first solvent stream being separated from a second solvent stream by an electrophoretic membrane;

(b) selecting a pH for the first solvent stream such that contaminants with an isoelectric point (pI) lower than the antibody to be separated will be charged;

35 (c) applying an electric potential between the two solvent streams causing movement of at least some of the contaminants through the membrane into

the second solvent stream while the antibody is substantially retained in the first solvent stream, or if entering the membrane, being substantially prevented from entering the second solvent stream:

5 (d) optionally, periodically stopping and reversing the electric potential to cause movement of any antibody having entered the membrane to move back into the first solvent stream, wherein substantially not causing any contaminants that have entered the second solvent stream to re-enter first solvent stream: and

10 (e) repeating step (c) and optionally step (d) until the first solvent stream contains the desired purity of antibody.

Preferably, the antibody and contaminant mixture is a monoclonal antibody in ascitic fluid.

In a preferred embodiment of the first aspect of the present invention, the electrophoretic membrane has a molecular mass cut-off of about 50 to 150 kDa, preferably about 100 kDa. The *pI* of the antibody to be separated is usually obtained by isoelectric focusing (IEF). The pH of the first solvent stream is preferably about 7.5 to 9.5. Major protein contaminants, including albumin whose *pI* is well known to be 4.9, can be separated from the antibodies by being caused to transfer into the second solvent stream at pH 8.3.

20 In a second aspect, the present invention consists in a method of separation of an antibody from a mixture of the antibody and at least one contaminant, the method comprising:

25 (a) placing the separated antibody in a first solvent stream, the first solvent stream being separated from a second solvent stream by an electrophoretic membrane;

(b) selecting a pH of the first solvent stream such that the pH is within 1 pH unit of the *pI* of the antibody;

(c) applying an electric potential between the two solvent streams causing movement of at least some of the contaminants through the membrane into the second solvent stream while the antibody is substantially retained in the first solvent stream, or if entering the membrane, being substantially prevented from entering the second solvent stream;

30 (d) optionally, periodically stopping and reversing the electric potential to cause movement of any antibody having entered the membrane to move back into the first solvent stream, wherein substantially not causing any

contaminants that have entered the second solvent stream to re-enter first solvent stream: and

(e) repeating step (c) and optionally step (d) until the first solvent stream contains the desired purity of antibody.

5 The electrophoretic membrane in step (a) preferably has a molecular mass cut-off at least about 200 kDa to ensure the contaminants can pass through to the second solvent stream. A cartridge containing a large 1000 kDa pore size separating-membrane has been found to be particularly suitable for this aspect of the present invention. The pH in step (b) is
10 typically from about 6 to 8.0. It will be appreciated that the pH of the buffer will depend on the *pI* of the antibody to be purified and the *pI*'s of the contaminants.

15 The pH of the buffer used in step (b) can be above or below the *pI* of the antibody to be separated. Preferably, the pH is within 0.5 pH units of the *pI* of the antibody.

In a third aspect, the present invention consists in a method of separation of an antibody from a mixture of the antibody and at least one contaminant, the method comprising:

20 (a - e) separating the antibody according to the first aspect of the present invention;

(f) placing the separated antibody in a fresh first solvent stream, the first solvent stream being separated from a second solvent stream by an electrophoretic membrane;

(g) selecting a pH of the fresh first solvent stream such that the pH is
25 within 1 pH unit of the *pI* of the antibody;

(h) applying an electric potential between the two solvent streams causing movement of at least some of the contaminants through the membrane into the second solvent stream while the antibody is substantially retained in the fresh first solvent stream, or if entering the membrane, being substantially
30 prevented from entering the second solvent stream;

(i) optionally, periodically stopping and reversing the electric potential to cause movement of any antibody having entered the membrane to move back into the fresh first solvent stream, wherein substantially not causing any contaminants that have entered the second solvent stream to re-enter first solvent stream: and

(j) repeating step (h) and optionally step (i) until the fresh first solvent stream contains the desired purity of antibody.

The molecular mass cut-off of the electrophoretic membrane used in step (f) is preferably larger than the membrane used in step (b). The electrophoretic membrane in step (f) preferably has a molecular mass cut-off at least about 200 kDa to ensure the contaminants can pass through to the second solvent stream. A cartridge containing a large 1000 kDa pore size separating-membrane has been found to be particularly suitable for this aspect of the present invention. The pH in step (g) is typically from about 6 to 8.0. It will be appreciated that the pH of the buffer will depend on the pI of the antibody to be purified and the pIs of the contaminants.

The pH of the buffer used in step (g) can be above or below the pI of the antibody to be separated. Preferably, the pH is within 0.5 pH units of the pI of the antibody.

The present inventors have been able to obtain percent recoveries of monoclonal antibodies from ascitic fluid of at least 70% and often greater than 90% using the methods according to the present invention.

A significant advantage of the present invention is that the separated antibody is less denatured or altered compared with the same antibody obtained by conventional antibody purification methods such as salt precipitation, Protein-A, Protein-G and ion-exchange chromatography.

In a fourth aspect, the present invention consists in use of Gradiflow in the purification and/or separation of antibodies.

In a fifth aspect, the present invention consists in an antibody purified by the method according to the first, second or third aspects of the present invention.

In order that the present invention may be more clearly understood, preferred forms will be described in the following examples with reference to the accompanying drawings.

30 Brief Description of Drawings

Figure 1 shows the operating modes of the Gradiflow separating cartridge. (a) Sized-based separation - this is a first step in which major contaminants are removed downstream from antibody mixture upstream. (b) Charge-based separation - this is a second step suitable to remove any residual contaminants if requiring antibodies of higher purity.

Figure 2 shows SDS-PAGE of the purification of antibody 4. Lane 1 is upstream at 0 min, lanes 2-5 upstream after 10, 20, 30, and 40 min, respectively. Lane 6-9 show downstream at 10, 20, 30, and 40 min, respectively. Lane 10 contains SDS molecular mass markers.

5 Mab=monoclonal antibodies; kDa=Kilodaltons.

Figure 3 shows SDS-PAGE of the purified monoclonal antibodies according to the second aspect of the present invention. Lane 1 and 7 are the SDS-PAGE molecular weight markers. For contrast, the starting material for antibody 1 was placed in lane 2 while lanes 3, 4, 5 and 6 contain the final 10 four product antibodies.

Modes for Carrying Out the Invention

EXPERIMENTAL

Antibodies

The antibodies used in this study were all generated by conventional 15 procedures (Bundesen et al 1985) and supplied to Gradipore Limited by Agen Biomedical Brisbane, Australia as murine ascitic fluids. Table I contains the properties of the target monoclonal antibodies.

20 Table 1. Monoclonal antibodies (recovery as determined by EIA)

Antibody	Isotype	pI	Recovery	
			%	mg/ml antibody
1	IgG1	pH 7.3-7.5	94 ^a	8.9
2	IgG2a	pH 6.7-7.7	73 ^b	8.1
3	IgG2b	pH 6.6-6.9	79 ^b	10.8
4	IgG1	pH 6.8-7.0	71 ^b	10.0

^a - denotes one step purification

^b - denotes a two-step purification

25 **Gradiflow technology**

The separating cartridge of the Gradiflow contains a set of 30 polyacrylamide-based restriction and separating membranes to enable the separation of macromolecules on the basis of size and/or charge (see Figure 1). A range of cartridges is available with M_r cut-offs ranging from 25,000 to 1,000,000. The ability to fractionate proteins over a range of pH and the use

of membranes of different pore sizes enables any target protein to be separated by virtue of its size or isoelectric point.

The Model LM1000 (Gradipore Limited, Sydney, Australia) contains peristaltic pumps, peltier coolers and power supply. It is controlled by a personal computer under a Windows 95 and Lab View format. Alternatively, a manually configured instrument is also available which can operate with conventional peristaltic pumps and power supply (Margolis et al 1995; Corthals et al 1996; Horvath et al 1996; Corthals et al 1997).

Modes of separation

Size-based separation (Figure 1a)

For size separation, a pH is selected at which all proteins have the same charge, in this case negative. Hence all of the proteins from the mixture circulating in the "upstream" compartment will try to migrate into the "downstream" compartment. If a membrane of restrictive pore size is selected, for example the M_r 100,000 used in this case, molecules larger than M_r 100,000 (such as the target antibodies) will be unable to transfer across the membrane and remain upstream. As essentially all proteins in mouse ascitic fluid have *pI* values less than pH 7.7, pH 8.3 was selected for size preparation in this paper. Under these conditions most of the ascitic proteins are transferred "downstream" leaving behind the M_r 160 000 antibody molecules.

Charged based separation (Figure 1b)

For charge-based separation, a pH is selected between the isoelectric points of two proteins such that one protein will have a positive charge and the other a negative charge. In this example, the protein mixture continuously circulates in the "upstream" compartment. When the current is applied, the negatively charged protein migrates through the membrane to the "downstream" compartment. Continuous circulation of the upstream and downstream compartments allows complete separation of the two proteins.

The vast majority of non-antibody proteins in murine ascitic fluid have isoelectric points below pH 6.5 so that at a pH above pH 6.5, these proteins are negatively charged and will migrate downstream leaving behind the antibody which normally has a *pI* above pH 6.6. For charge separations, a membrane with a large pore size is usually employed (M_r 1 x 10⁶) to allow for maximum transport across the membrane.

Purification of monoclonal antibodies

Each sample of ascitic fluid (0.5 - 2 ml) was diluted with at least three volumes of a buffer containing 40 mM Tris-borate, 1 mM EDTA pH 8.3.

Firstly a size separation of each sample was carried out in this buffer for 30 to 40 min at 200 V with a M_r cut-off 100,000 separating membrane. Under these conditions, albumin and other impurities rapidly migrated across the membrane leaving behind the purified antibody upstream.

For higher purity, a second run was selected at a pH close to the pI of each specific antibody using a M_r cut-off 1×10^6 membrane. For example 40 mM Tris buffer can be adjusted to the required pH with acetic acid. The run time was 40 min at 200 V. The remaining impurities migrated through the membrane while the antibody remained upstream. By taking 50 μ l aliquots of upstream and downstream at 10-min intervals during the first and second run, the purity of the target antibodies was then determined by denaturing sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The percent recovery was determined by enzyme immunoassay (EIA) after the runs were completed.

The upstream and downstream were harvested after 40 min. For maximum recovery of antibody, a small amount (7 ml) of running buffer was pumped in the upstream and downstream for a minute at the end of the separation process with the current reversed. After the current reversal was switched off, the upstream and downstream were allowed to circulate for another minute before the upstream wash was harvested and combined with the initial antibody harvested. An additional 10-15% of antibody can be recovered in this washing process

Isoelectric focusing

The pI of each antibody was determined by running an isoelectric focusing (IEF) gel using a Novex (San Diego CA, USA) IEF gel apparatus as described by the manufacturer. Briefly, the running conditions involved a run time of 1 h at 100 V 1 h at 200 V and 500 V for 30 min. The IEF gel was fixed with a solution of 12% (w/v) trichloroacetic acid (Sigma Product No T8657) with 3.5% (w/v) 5-sulfosalicylic acid (Sigma Product No S-3147) in deionised water for 30 min before staining with Gradipure™ Coomassie Blue.

Determination of antibody purity

Samples were analysed by SDS-PAGE on Gradipore 4-20% T SDS gels [$T = (g \text{ acrylamide} + g \text{ } N,N\text{-methylenebisacrylamide})/100 \text{ ml solution}$]. The changes to sample purity with time were determined by comparing the 5 protein bands upstream and downstream at different times.

Determination of antibody recovery*Protein concentration*

Protein levels in the upstream and downstream were determined by measuring the ultraviolet absorption at 280 nm. A 1 mg/ml solution of mouse 10 monoclonal antibodies was assumed to have an absorbance of 1.2 AU.

Enzyme immunoassay

The antibody activity was determined by a two-site EIA using either antigen or unlabelled sheep anti-mouse immunoglobulin as the capturing component. The microplate was first coated with either 50 μl of antigen (10 $\mu\text{l}/\text{ml}$) or rabbit anti-mouse immunoglobulins (10 $\mu\text{l}/\text{ml}$) Dako (Carpinteria, 15 USA) in phosphate-buffered saline (PBS) pH 7.4 for 1 h at room temperature.

Excess antigen was removed by inverting and tapping the plate and the plate was washed three times with PBS containing 0.1% Tween 20 (PBS/T). Next, 50 μl of a suitable dilution in PBS/T of the monoclonal fraction under 20 test was added and the incubation was allowed to proceed for an hour at room temperature. After removal of unbound antibody by washing, bound antibody was labelled by the addition of a 1/1000 dilution of horseradish peroxidase (HRPO)-labelled anti anti-mouse antibody and incubated for another hour. Finally, the bound enzyme detected after further washing by 25 the addition of substrate and stop solutions.

RESULTS AND DISCUSSION**Isoelectric focusing**

IEF is a technique that enables proteins to be characterised by their *pI* values which can be used to determine the best conditions for a charge based 30 separation. An IEF gel of the starting material showed that each ascitic fluid had a unique IEF pattern with the major difference being the position of the multiple bands of target antibodies.

The IEF gel indicated a range of *pI* values from 6.6 to 7.7 for the four 35 different antibodies derived from ascitic fluid samples. The *pI* values of the antibodies are listed in Table 1. The variety of isoforms provides plausible reason for the low recoveries from conventional ion-exchange protocols for

antibodies as the charge heterogeneity could cause multiple broad peaks and tailing effects.

Purification of mouse antibodies

Size separation

5 Size exclusion was chosen as the first step when IEF (Figure 1) revealed a wide variation in the isoelectric charge of individual antibodies. A membrane with a M_r cut-off of 100,000 was selected as this pore size should retain the M_r 160,000 antibody, yet allow the rapid passage of smaller protein molecules. A pH of 8.3 was chosen so that the majority of immune ascitic

10 fluid proteins had net negative charges at this pH.

A time course for the purification of antibody 4 is depicted in Figure 2. Similar results were obtained for the other three antibodies. After 20 min. the most significant bands in the sample stream are the characteristic heavy and light chains of the monoclonal antibody. Acceptable purity was 15 achieved after 30 min (lane 5 in Figure 2) without substantial improvement at 40 min. Lower-molecular-mass proteins with the most abundant being mouse serum albumin. rapidly passed through the M_r 100,000 membrane leaving behind the antibody upstream. The downstream was harvested every 10 min and showed decreasing amounts of protein in each subsequent harvest (Figure 2. lanes 7-9). Most of the impurities were removed from the antibody in the first 10 min (lane 7) with large amounts of albumin present in the two initial downstream harvests that were collected at 10 min and 20 min. Albumin had disappeared from the upstream after 10 min. This ending was interpreted. as residual albumin found downstream in the 10-min sample 20 being in transit within the separation membrane when the 10-min sample was taken.

These conditions were chosen for initial separation with a view to try to select a universal first step that would allow the purification of any antibody in good yield with the high degree of purity. The Tris-borate buffer 30 was selected because it has proven to be a useful buffer for separations under native conditions in many other applications. The voltage was selected on the basis of the required speed of the separation with the aim of completing the process in less than 30 min. For most applications. the higher the voltage the more rapid the purification.

Some antibodies are thought to be labile at room temperature and there are many reports that temperature can affect protein folding with lower temperatures increasing protein volubility.

Charge separation

5 A higher degree of purity for each antibody can be achieved in a charged-based second step carried out at a pH near the *pI* of each antibody. As the isoelectric points vary, this meant a different pH was selected for each antibody. During the separations using either size or charge, there was no evidence that the solubility of each target antibody was affected by a pH 10 higher than its *pI* or near its *pI*. The solubility of the proteins remained excellent with these operating conditions and choice of buffers used. Each different antibody solution was adjusted with acetic acid to the pH that was close to the *pI* prior to a charge separation. The membrane used for the charge separation was a $M_r 1 \times 10^6$ pore size to increase the speed of removal 15 of the contaminating proteins. Under these conditions, the monoclonal antibody now uncharged, remained upstream and the contaminating negatively charged proteins migrated downstream SDS-PAGE (Figure 3) indicated that a high degree of purity was achieved for all antibodies using this second step. The relatively high *pI* of antibody 1 allowed this antibody 20 to be purified in a single step at pH 8.3 using $M_r 1 \times 10^6$ pore size membrane (instead of $M_r 100,000$). This antibody was expected to migrate through the $M_r 1 \times 10^6$ membrane because it did have a small negative charge at this pH but for short runs of less than an hour, it remained upstream. Indeed with longer separation times (1-2 h) some migration downstream was noted.

25 Recovery

The recovery of the monoclonal antibodies was determined by comparing the final biological activity of the antibody present upstream, downstream and in the washes with the starting material (Table I). Although recoveries for antibodies 2, 3 and 4 (using two-stage purifications) 30 were less than for antibody 1 (Table 1) quantities of >8 mg of each antibody were recovered per ml of ascitic fluid. This recovery was higher than the expected yields for other purification procedures. These higher activities recovered may be due to a combination of the mild buffers used the relatively short distance required for separation to occur with the separation cartridge 35 and the short purification times.

The protocol developed takes the advantage of the large size (M_r , 160,000) of the monoclonal antibodies relative to other proteins in ascitic fluid and their relatively high pI values compared to other proteins in murine ascitic fluid. The protocol described here is less complex than conventional chromatographic purification techniques where more variables need to be considered. The immunoglobulin fraction is usually about 2-25% of the total protein in ascitic fluids. The high content of lipid present in ascitic fluid is known to reduce the life of fractionation columns. In the present experiments, excellent purification and recovery without the need to delipidise or pretreat the samples was achieved.

Initially, small amounts (10-20 mg) of each target antibody were purified to test the invention. Linear scale up from the 15 cm² membranes (used here) to 200 cm² has been accomplished by the present inventor and co-workers previously for haemoglobin/albumin separations (Horvath et al 1994). Preliminary scale up from 2 ml to 10 ml of mouse ascites fluid on the 15 cm² cartridges was achieved. Longer processing time or a larger separation cartridges may be required for larger quantities of proteins.

Comparison of antibodies separated according to the present invention with the same antibodies purified by standard techniques including Protein-A, Protein-G and ion exchange chromatography by a collaborating third party revealed the antibodies obtained by the present invention were more active. Furthermore, the yields of antibodies were greater using the present invention. Tables 2 and 3 show the results of the comparisons of several purifications of antibodies.

Table 2 Yield of Mouse IgG1 monoclonal antibody

Purification Method	Yield (mg antibody recovered)
Protein-A	65
Invention	68
Ion exchange	60

Table 3. Yield of Rat IgG2b monoclonal antibody

Purification Method	Yield (%)
Protein-G	83
Invention	91
Ion exchange	81

5 Electrophoretic analysis (SDS-PAGE) of antibodies purified by the present invention revealed lower number of protein bands indicating that the present method does not cleave or damage the antibodies compared with other purification techniques. Not only can the present invention provide greater yields of antibody, the invention also provides more active and less denatured antibody preparations.

10 Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

15 It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

REFERENCES

PG Bundesen, DM Wyatt, LE Cottis, AS Blake, DA Massingham, WA Fletcher, G Street, JS Welch, DB Rylatt *Vet Immunol Immunopath* 8 (1985) 245-260.

5 Horvath ZC, Corthals GL, Wrigley CW and Margolis J. Multifunctional apparatus for electrokinetic processing of proteins. *Electrophoresis* 1994 15 968-971.

10 Margolis J, Corthals G and Horvath ZS. Preparative reflux electrophoresis. *Electrophoresis* 1995 16 98-100.

15 Corthals GL, Margolis J, Williams KL and Gooley AA. The role of pH and membrane porosity in preparative electrophoresis. *Electrophoresis* 1996 17 771-775.

20 Horvath ZC, Gooley AA, Wrigley CW, Margolis J and Williams KL. Preparative affinity membrane electrophoresis. *Electrophoresis* 1996 17 224-226.

Corthals GL, Molloy MP, Herbert BR, Williams KL and Gooley AA. Prefractionation of protein samples prior to two-dimensional electrophoresis. *Electrophoresis* 1997 18 317-323.

CLAIMS:

1. A method of separating an antibody from a mixture of antibody and at least one contaminant, the method comprising:

(a) placing the antibody and contaminant mixture in a first solvent stream, the first solvent stream being separated from a second solvent stream by an

5 electrophoretic membrane having a molecular mass cut-off of 50 to 150 kDa;

(b) selecting a pH of 7.5 to 9.5 for the first solvent stream such that

contaminants with an isoelectric point (*pI*) lower than the antibody to be separated will be charged:

10 (c) applying an electric potential between the two solvent streams causing movement of at least some of the contaminants through the membrane into the second solvent stream while the antibody is substantially retained in the first solvent stream, or if entering the membrane, being substantially prevented from entering the second solvent stream;

15 (d) optionally, periodically stopping and reversing the electric potential to cause movement of any antibody having entered the membrane to move back into the first solvent stream, wherein substantially not causing any contaminants that have entered the second solvent stream to re-enter the first solvent stream; and

20 (e) repeating step (c) and optionally step (d) until the first solvent stream contains the desired purity of antibody, wherein the recovery of the antibody is at least 70% and the antibody being less denatured or altered compared with the same antibody obtained by conventional antibody purification methods.

25 2. The method according to claim 1 wherein the antibody and contaminant mixture is a monoclonal antibody in ascitic fluid.

3. The method according to claim 1 or 2 wherein the electrophoretic membrane has a molecular mass cut-off of 100 kDa.

30 4. The method according to any one of claims 1 to 3 further including the steps of:

(f) placing the separated antibody in a fresh first solvent stream, the fresh first solvent stream being separated from a second solvent stream by an electrophoretic membrane having a molecular mass cut-off larger than that of the electrophoretic membrane used in step (b);

35 (g) selecting a pH of the fresh first solvent stream such that the pH is within 1 pH unit of the *pI* of the antibody;

(h) applying an electric potential between the two solvent streams causing movement of at least some of the contaminants through the membrane into the second solvent stream while the antibody is substantially retained in the fresh first solvent stream, or if entering the membrane, being substantially prevented from entering the second solvent stream:

(i) optionally, periodically stopping and reversing the electric potential to cause movement of any antibody having entered the membrane to move back into the fresh first solvent stream, wherein substantially not causing any contaminants that have entered the second solvent stream to re-enter the fresh first solvent stream; and

(j) repeating step (h) and optionally step (i) until the fresh first solvent stream contains the desired purity of antibody, wherein the recovery of the antibody is at least 70%.

5. The method according to claim 4 wherein the molecular mass cut-off of the electrophoretic membrane used in step (f) is at least 200 kDa.

6. The method according to claim 4 wherein the molecular mass cut-off of the electrophoretic membrane used in step (f) is 1000 kDa.

7. The method according to any one of claims 4 to 6 wherein the pH of the fresh first solvent stream in step (g) is from 6 to 8.

20. 8. The method according any one of claims 4 to 6 wherein the pH of the fresh first solvent stream in step (g) is within 0.5 pH units of the pI of the antibody.

9. The method according to any one of claims 1 to 8 wherein recovery of the antibody is at least 90%.

25. 10. A method of separating an antibody from a mixture of antibody and at least one contaminant, the method comprising:

(a) placing the antibody and contaminant mixture in a first solvent stream, the first solvent stream being separated from a second solvent stream by an electrophoretic membrane having a molecular mass cut-off of at least 200 kDa;

(b) selecting a pH of the first solvent stream such that the pH is within 1 pH unit of the pI of the antibody;

(c) applying an electric potential between the two solvent streams causing movement of at least some of the contaminants through the membrane into the second solvent stream while the antibody is substantially retained in the

first solvent stream, or if entering the membrane, being substantially prevented from entering the second solvent stream;

(d) optionally, periodically stopping and reversing the electric potential to cause movement of any antibody having entered the membrane to move back into the first solvent stream, wherein substantially not causing any 5 contaminants that have entered the second solvent stream to re-enter the first solvent stream; and

(e) repeating step (c) and optionally step (d) until the first solvent stream contains the desired purity of antibody, wherein the recovery of the antibody 10 is at least 70% and the antibody being less denatured or altered compared with the same antibody obtained by conventional antibody purification methods.

11. The method according to claim 10 wherein the antibody and contaminant mixture is a monoclonal antibody in ascitic fluid.

12. The method according to claim 10 or 11 wherein the molecular mass cut-off of the electrophoretic membrane used in step (a) is 1000 kDa.

13. The method according to any one of claims 10 to 12 wherein the pH of the first solvent stream in step (b) is from 6 to 8.

14. The method according to any one of claims 10 to 12 wherein the pH of the first solvent stream in step (b) is within 0.5 pH units of the pI of the antibody.

15. The method according to any one of claims 10 to 14 wherein recovery of the antibody is at least 90%.

16. An isolated antibody purified by the method according to any one of claims 1 to 15.

20 17. The isolated antibody according to claim 16 being a monoclonal antibody.




Figure 1




Figure 2




Figure 3

Attorney Docket No.: 071550.0022
Your Ref. No.: 102552
International Ap #:PCT/AU99/00424
Int'l Filing Date: 06/02/99

DECLARATION AND POWER OF ATTORNEY

(Original Application)

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

PURIFICATION OF ANTIBODIES

the specification of which is attached hereto and/or was filed on December 1, 2000 as Application No. 09/701,818.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to herein.

I acknowledge the duty to disclose information which is material to patentability in accordance with Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d), of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

FOREIGN PRIORITY APPLICATION(S)

PP3855 (Number)	AUSTRALIA (Country)	02/JUNE/1998 (Day/month/year filed)	Priority Claimed [x] Yes [] No
_____	_____	_____	Priority Claimed [] Yes [] No.

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional patent application(s) listed below and have also identified below any United States provisional patent application(s) having a filing date before that of the application on which priority is claimed:

PROVISIONAL PRIORITY PATENT APPLICATION(S)

		<u>Priority Claimed</u>
(Application No.)	(Filing Date)	<input type="checkbox"/> Yes <input type="checkbox"/> No
		<u>Priority Claimed</u>
(Application No.)	(Filing Date)	<input type="checkbox"/> Yes <input type="checkbox"/> No

And I hereby appoint the registered attorneys and agents associated with **AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.**, Customer No. 000027000, as my attorneys or agents with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Address all correspondence to **Customer No. 000027000, namely, AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.**, 1333 New Hampshire Avenue, N.W., Suite 400, Washington, D.C. 20036. Please direct all communications and telephone calls to

Alex Chartove
AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.
1333 New Hampshire Avenue, N.W.
Suite 400
Washington, D.C. 20036
Phone: (202) 887-4149
Fax: (202) 955-7613
e-mail: achartove@akingump.com

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full name of sole
or first inventor

DENNIS BRIAN RYLATT

Inventor's Signature

Dennis B Rylatt

Date

16/01/01

Residence

10 Stuart Street, Ryde, NSW. 2112. AUSTRALIA

Aux

Citizenship

AUSTRALIAN

Post Office

10 Stuart Street, Ryde, NSW. 2112. AUSTRALIA

Address

Full name of second

joint inventor, if any

SHARON LIM

Inventor's Signature

Sharon Lim

Date

19/01/01

Residence

28/61-89 Buckingham Street, Surry Hills, NSW. 2010. AUSTRALIA

Aux

Citizenship

AUSTRALIAN

Post Office

28/61-89 Buckingham Street, Surry Hills, NSW. 2010. AUSTRALIA

Address

Full name of third

joint inventor, if any

Inventor's Signature

Date

Residence

Citizenship

Post Office

Address